https://scholars.lib.ntu.edu.tw/handle/123456789/584489
標題: | Optimal usage of radium-223 in metastatic castration-resistant prostate cancer | 作者: | Cha T.-L. Wu T.T.-L. Vogelzang N.J. CHAO-YUAN HUANG Huang S.-P. CHIA-CHI LIN Ou Y.-C. Pang S.-T. Shen D.H.-Y. Wu W.-J. Chang W.Y.-H. |
公開日期: | 2017 | 出版社: | Elsevier B.V. | 卷: | 116 | 期: | 11 | 起(迄)頁: | 825-836 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Radium-223 is a first-in-class α-emitting radiopharmaceutical that targets bone metastases associated with metastatic castration-resistant prostate cancer (mCRPC). In the pivotal phase III trial ALSYMPCA, radium-223 significantly increased overall survival (OS), compared with placebo (median 14.9 vs 11.3 months; hazard ratio 0.70; 95% CI 0.58–0.83; p < 0.001), in patients with mCRPC and symptomatic bone metastases–with a comparable safety profile. To optimize treatment outcomes, selection of appropriate patients is important. As well as osteoblastic bone metastases, mCRPC patients should be well enough to receive six doses of radium-223 as this treatment duration has been shown to greatly improve OS outcomes compared with administration of four or fewer doses. Additionally, alkaline phosphatase and lactate dehydrogenase are emerging as important biomarkers during radium-223 treatment. Optimal concomitant standard-of-care therapies (such as abiraterone or enzalutamide) to be administered with radium-223 have yet to be defined as does the most efficacious dose and duration of radium-223 treatment. In conclusion, radium-223 is an important addition to the mCRPC treatment landscape and marks a paradigm shift in the treatment of bone metastases. ? 2017 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031400097&doi=10.1016%2fj.jfma.2017.04.005&partnerID=40&md5=264b5c6c80c8e4e881ee298872b770a3 https://scholars.lib.ntu.edu.tw/handle/123456789/584489 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2017.04.005 | SDG/關鍵字: | abiraterone; abiraterone acetate; alkaline phosphatase; biological marker; enzalutamide; lactate dehydrogenase; radium chloride ra 223; radiopharmaceutical agent; radium; Radium-223; anemia; aplastic anemia; backache; bone marrow suppression; bone metastasis; bone pain; cancer survival; castration resistant prostate cancer; diarrhea; drug efficacy; drug safety; fatigue; fever; follow up; hot flush; human; hypertension; liver toxicity; neutropenia; osteoblast; overall survival; patient selection; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); Review; seizure; spinal cord compression; systematic review; thrombocytopenia; treatment duration; treatment outcome; bone tumor; castration resistant prostate cancer; clinical trial (topic); male; pathology; secondary; Bone Neoplasms; Clinical Trials as Topic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radium; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。